- Home
- RSLS vs ENTO Comparison
RSLS vs ENTO Comparison
Compare RSLS & ENTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSLS
- ENTO
- Stock Information
- Founded
- RSLS 2002
- ENTO 2014
- Country
- RSLS United States
- ENTO United States
- Employees
- RSLS N/A
- ENTO N/A
- Industry
- RSLS Medical/Dental Instruments
- ENTO Biotechnology: Pharmaceutical Preparations
- Sector
- RSLS Health Care
- ENTO Health Care
- Exchange
- RSLS Nasdaq
- ENTO Nasdaq
- Market Cap
- RSLS 3.1M
- ENTO 2.8M
- IPO Year
- RSLS 2007
- ENTO 2016
- Fundamental
- Price
- RSLS $4.38
- ENTO $0.63
- Analyst Decision
- RSLS Hold
- ENTO
- Analyst Count
- RSLS 1
- ENTO 0
- Target Price
- RSLS N/A
- ENTO N/A
- AVG Volume (30 Days)
- RSLS 30.3K
- ENTO 349.4K
- Earning Date
- RSLS 11-14-2024
- ENTO 11-13-2024
- Dividend Yield
- RSLS N/A
- ENTO N/A
- EPS Growth
- RSLS N/A
- ENTO N/A
- EPS
- RSLS N/A
- ENTO N/A
- Revenue
- RSLS $8,183,000.00
- ENTO N/A
- Revenue This Year
- RSLS $17.47
- ENTO N/A
- Revenue Next Year
- RSLS $20.00
- ENTO N/A
- P/E Ratio
- RSLS N/A
- ENTO N/A
- Revenue Growth
- RSLS N/A
- ENTO N/A
- 52 Week Low
- RSLS $4.09
- ENTO $0.19
- 52 Week High
- RSLS $29.00
- ENTO $14.51
- Technical
- Relative Strength Index (RSI)
- RSLS 32.94
- ENTO 54.83
- Support Level
- RSLS $4.09
- ENTO $0.52
- Resistance Level
- RSLS $4.80
- ENTO $0.67
- Average True Range (ATR)
- RSLS 0.40
- ENTO 0.12
- MACD
- RSLS -0.06
- ENTO 0.00
- Stochastic Oscillator
- RSLS 18.24
- ENTO 36.48
About RSLS ReShape Lifesciences Inc.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.
About ENTO Entero Therapeutics Inc. Common Stock
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.